72 results
6-K
EX-99.3
FENC
Fennec Pharmaceuticals Inc
12 Aug 05
Adherex Reports Second Quarter 2005 Financial Results
12:00am
of our product candidates. Research and development (“R&D”) expenses, which include expenses associated with clinical development activities … , 2005
The increase in the net loss for the quarters ended June 30, 2005, March 31, 2005 and December 31, 2004 is due to the increased R&D efforts
6-K
EX-99.3
FENC
Fennec Pharmaceuticals Inc
11 May 05
Adherex Reports First Quarter 2005 Financial Results
12:00am
of our drug development efforts and the potential commercialization of our product candidates. Research and development (“R&D”) expenses, which … .
Research and Development Expenses
R&D expenses for the three-month period ended March 31, 2005 totaled $2.0 million as compared to $1.2 million for the same
6-K
EX-99.3
FENC
Fennec Pharmaceuticals Inc
9 Aug 06
Adherex Reports Second Quarter 2006 Financial Results
12:00am
of our product candidates. Research and development (“R&D”) expenses, which include expenses associated with clinical development activities … , such as licensing fees, upfront payments, royalties, milestone payments or otherwise.
Research and Development Expenses
R&D expenses for the three
6-K
EX-99.3
hismkk49j99as2
16 May 06
Adherex Reports First Quarter 2006 Financial Results
12:00am
6-K
h2f 8wixl2ouh1j638p
12 Nov 04
Current report (foreign)
12:00am
8-K
EX-99.1
082i32j8d80f datl
9 May 19
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results
4:40pm
8-K
EX-99.1
u3ft5f7krg76r1tk74pe
9 Aug 19
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
11:15am
8-K
EX-99.1
0lagl 1tftjbv
14 Mar 19
Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
6:02am